January 2023 is the World Health Organization’s Cervical Cancer Awareness Month. The aim for WHO and its partners to raise awareness about cervical cancer and HPV vaccination. This year, the focus is on ending cervical cancer within a few generations as the theme for Cervical Cancer Awareness Month. When diagnosed, cervical cancer is one of the most successfully treatable forms of cancer, as long as it is detected early and managed effectively. Cancers diagnosed in late stages can also be controlled with appropriate treatment and palliative care. With a comprehensive approach to prevent, screen and treat, cervical cancer could be ended as a public health problem within a few generations.
Olink would like to take this opportunity to raise awareness of recent research developments in diagnostics and monitoring of cervical cancer. Cervivor, a US-based non-profit organization that brings cervical cancer survivors together, interviewed Professor Ulf Gyllensten (Department of Immunology, Genetics and Pathology at Uppsala University) about his work on developing a signature of proteins to identify women with cervical cancer, using Olink’s Proximity Extension Assay technology.
Professor Gyllensten emphasizes the importance of collaborative efforts to improve strategies and infrastructure for cervical cancer screening for women across the globe and his efforts to empower women in Africa with self-sampling kits. He also speaks about the latest research to develop a self-sampling kit covering other major gynecological cancers such as ovarian and endometrial cancers. At Olink we are proud to be part of this exciting journey, focusing on the improvement of women’s health.
